Preventive Efficacy of Domestic Vaccines against a New Coronavirus Infection in the Immunization of Employees of Medical Organizations

Relevance. Evaluation of the preventive effectiveness of domestic vaccines in immunization of employees of medical organizations, in the context of the ongoing pandemic caused by the SARS-CoV-2 virus, remains important. The aim. To evaluate the preventive effectiveness of domestic vaccines in the immunization of employees of medical organizations. Materials and methods. The preventive efficacy of domestic vaccines was studied in an epidemiological, analytical, retrospective (historical), cohort, parallel study involving 1115 healthcare workers from various outpatient and policlinic organizations in the city of Perm. Results. The high preventive efficacy of COVID-19 vaccination of health care workers was established in the conditions of analytical cohort study (the incidence of the unvaccinated was 3.3 times higher than the incidence of vaccinated). Among the vaccinated, a milder course of the disease was observed. The GamCovidVac Spuntic V and Sputnik Light vaccines were characterized by the highest prophylactic efficacy for which was 76.1 and 78.2 respectively, against 54.53 with Covivac immunization and 50.7 with EpiVacCorona. Conclusions. Vaccination is an effective measure against COVID-19 and can be recommended in the context of ongoing pandemic.

1. Bchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020 Nov;13(11):1601–1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4. PMID: 32778421; PMCID: PMC7402212.

2. Hughes M.M., Groenewold M.R., Lessem S.E., et al. Update: Characteristics of HealthCare Personnel with COVID-19 - United States, February 12-July 16, 2020. MMWR Morb Mortal Wkly Rep. 2020. Vol. 69. N. 38. P. 1364–1368.

3. Kambhampati AK, O’Halloran AC, Whitaker M, et al. COVID-19–Associated Hospitalizations Among Health Care Personnel – COVID-NET, 13 States, March 1–May 31, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1576–1583. DOI: http://dx.doi.org/10.15585/mmwr.mm6943e3.

4. Treibel T.A., Manisty C., Burton M., et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet. 2020. Vol. 395. N10237. P.1608–1610. DOI: 10.1016/S0140-6736(20)31100-4.

5. Hunter E., Price D.A., Murphy E., et al. First experience of COVID-19 screening of health-care workers in England. LСмancet. 2020. Vol. 395. N10234. P.77–78. DOI: 10.1016/S0140-6736(20)30970-3.

6. Nguyen L. H., Drew D. A., Joshi A. D., et al. Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study. // Lancet Public Health. 2020. N 5. P. 475–483. DOI:https://doi.org/10.1016/S2468-2667(20)30164-X.

7. Kurylev A.A., Zhuravkov A.A., Kolbin A.S. Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2021;(4):80-84. (In Russ.) https://doi.org/10.37489/2588-0519-2021-4-80-84.

8. Dmitriev A.V., Fedinа N.V., Tkachenko T.G., et al. Preventive vaccination compliance among medical students and pediatricians during the COVID-19 pandemic. Meditsinskiy sovet = Medical Council. 2021;(11):202–209. (In Russ.) https://doi.org/10.21518/2079-701X-2021-11-202-209

9. Palamenghi L, Barello S, Boccia S, Graffigna G. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. EurJ-Epidemiol. 2020 Aug;35(8):785–788. doi: 10.1007/s10654-020-00675-8.

10. Golubkova A.A., Platonova T.A., Semenenko T.A., Smirnova S.S., Nikitskaya A.D., Chikunova M.V. Multi-Level Monitoring of Vaccination Adherence of Various Population Groups in the Context of the COVID-19 Pandemic: Problematic Issues. Epidemiology and Vaccinal Prevention. 2021;20(6):28–36. (In Russ.) https://doi.org/10.31631/2073-3046-2021-20-6-28-36.

11. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020; 52 (5): 737–741. doi: 10.1016/j.immuni.2020.04.012.

12. Lourenço J, Paton R, Thompson C, Klenerman P, Gupta S. Fundamental principles of epidemic spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic. MedRxiv. 2029; 2004229. doi.org/10.1101/2020.03.24.2004229.

13. Vignesh R, Shankar EM, Velu V, Thyagarajan SP. Is Herd Immunity Against SARS-CoV-2 a Silver Lining? Front Immunol. 2020; 11: 586781. doi: 10.3389/fimmu.2020.586781

14. Popova A.Yu., Ezhlova E.B., Melnikova A.A., et al. Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic. Problems of Particularly Dangerous Infections. 2020;(3):124–130. (In Russ.) https://doi.org/10.21055/0370-1069-2020-3-124-130

15. Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021, 397, 671–681, doi:10.1016/S0140-6736(21)00234-8.

16. Vokó Z, Kiss Z, Surján G. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary - The HUN-Estudy.ClinicalMicrobiologyandInfection2021,2021 DOI:https://doi. org/10.1016/j.cmi.2021.11.011

17. Namazova-Baranova Leyla S., Fedoseenko Marina V., Shakhtakhtinskaya Firuza Ch., et al. Efficacy and Safety of Peptide Vaccine in Prevention of SARS-CoV-2 Infection: Prospective Study among Healthcare Professionals. Voprosy sovremennoi pediatrii — Current Pediatrics. 2022;21(2):83–94. (In Russ). doi: https://doi.org/10.15690/vsp.v21i2.2386.

18. Ryzhikov A.B., Ryzhikov E.A., Bogryantseva M.P., et al. A simple blind placebocontrolled randomized study of the safety, reactogenicity and immunogenicity of the EpiVac Corona vaccine for the prevention of COVID-19 on volunteers aged 18–60 years (phase I–II). Infektsiya i immunitet [Russian Journal of Infection and Immunity]. 2021; 11 (2): 283–96. (in Russian). DOI: https://doi.org/10.15789/2220-7619-ASB-1699 15. Temporary methodological recommendations “Procedure for vaccination of the adult population against COVID-19”; 2021. (in Russian).

19. Sergienko D. F., Kuz’min E. A., Emeeva Z. Y., Kosareva A. R., Abdulaeva P. M., Pogosyan K. A., Zaplavnyy V. M. Vaccination against COVID 19: prejudice, preconception and truth. Astrakhan Medical Journal. 2022; 17 (2): 14–20. doi: 10.48612/agmu/2022.17.2.14.20 (In Russ.).

20. Barchuk A, BulinaA, Cherkashin M, et al. COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia. Now published in BMC Public Health. doi:10.1186/s12889-022-14202-9

21. Logunov, D.Y., Dolzhikova, I.V., Zubkova, O.V., et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet 2020, 396, 887–897.

22. Dolzhikova, I.V.; Gushchin, V.A.; Shcheblyakov, D.V., et al. One-shotimmunization with Sputnik Light (the first component of Sputnik V vaccine) is effective againstSARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow.medRxiv2021,10.1101/2021.10.08.21264715, doi:10.1101/2021.10.08.21264715.

23. González S, Olszevicki S, Salazar M, Calabria A, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine. Volume 40.2021.101126. ISSN 2589–5370. https://doi. org/10.1016/j.eclinm.2021.101126.

24. Kolobukhina L.V., Burgasova O.A., Kruzhkova I.S., et al. Assessment of COVID-19 clinical course in patients vaccinated with Sputnik V, SARS-CoV-2 S protein RBD domain variation and serum virus neutralizing activity. Bulletin of Russian State Medical University 2021; (5):62–70. https://doi.org/10.24075/brsmu.2021.046

25. Butt A.A., Nafady-Hego H., Chemaitelly H., Abou-Samra A.B., Khal A.A., Coyle P.V., Kanaani Z.A., Kaleeckal A.H., Latif A.N., Masalmani Y.A., Bertollini R., Raddad L. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. Int. J. Infect. Dis. 2021; 110:353–358. https://doi.org/10.1016/j.ijid.2021.08.008.